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Whole genome DNA sequencing was used to decrypt the phylogeny of multiple samples from 
distinct areas of cancer and morphologically normal tissue taken from the prostates of three men. 
Mutations were present at high levels in morphologically normal tissue distant from the cancer 
reflecting clonal expansions, and the underlying mutational processes at work in morphologically 
normal tissue were also at work in cancer. Our observations demonstrate the existence of on-
going abnormal mutational processes, consistent with field-effects, underlying carcinogenesis. 
This mechanism gives rise to extensive branching evolution and cancer clone mixing as 
exemplified by the coexistence of multiple cancer lineages harboring distinct ERG fusions within a 
single cancer nodule.  Subsets of mutations were shared either by morphologically normal and 
malignant tissue or between different ERG-lineages, indicating earlier or separate clonal cell 
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expansions. Our observations inform on the origin of multifocal disease and have implications for 
prostate cancer therapy in individual cases.  
Prostate cancer is commonly multifocal1, although the origin of multifocal disease remains 
controversial. Analyses of patterns of allele loss have suggested the independence of most individual 
foci2,3. However such studies cannot exclude the presence of common underlying mutations not 
detected by the methods employed. Recent attempts to unravel the origins of multifocal disease 
using high-resolution genome technologies have also led to conflicting data with different authors 
concluding either that all foci in a single prostate are related4  or that all foci are unrelated5.  To gain 
further insights into the mechanism of prostate cancer development particularly the origin of 
multifocal disease we selected three representative prostate cancers (Fig.1, Supplementary Fig.1) 
that had been ERG-status mapped using the FISH break-apart method6,7 . Twelve cancer samples and 
three samples designated as morphologically normal prostate based on central pathology review, 
were analyzed using paired-end massively-parallel DNA sequencing of complete genomes to 
generate comprehensive catalogues of genetic alterations (for coverage statistics see 
Supplementary Table 1).  For 3D representations of each prostate and clinical characteristics see 
respectively Supplementary Fig. 2 and Supplementary Table 2.  Prostates were named according to 
their Cancer Research UK project designation: Cases 6, 7 and 8.  
Somatic mutations, absent from cancer and blood samples, were observed at significant levels in 
morphologically normal prostate tissue distant from cancer in Case 6 (518 substitutions) and in Case 
7 (454 substitutions) (Supplementary Fig. 3), some of which may have potential functional 
significance (Table 1). The presence of substitution mutations in morphologically normal prostate 
tissue was confirmed in validation DNA-sequencing experiments to an average read depth of 10,000.  
Substitutions were present in an estimated ~48%, and ~42% of cells in morphologically normal 
samples from Case 6 and Case 7 respectively (Supplementary Fig. 3b)), demonstrating clonal 
expansions of cells within morphologically normal prostate tissue, in agreement with studies using 
mitochondrially-encoded enzyme cytochrome c oxidase as a marker8 .  
Aiming to understand the tumor subclonal architecture and their phylogeny, we initially constructed 
phylogenetic trees based on copy number (Supplementary Fig. 4 & 5, Supplementary Data Set 1) 
and substitution data.  We adapted our previously developed Bayesian Dirichlet process to identify 
clusters of substitutions in n dimensions9, where n is the number of samples from the case, such that 
shared and unique subclones could be identified between related samples (Fig. 2d and 
Supplementary Fig. 6). To further explore the fine details and verify the main features of the 
phylogeny tree and clonal structure, a selection of substitutions from each potential relationship 
 4 
between samples were sequenced to an average read depth of 10,000 in independent DNA 
sequencing analyses, verifying 279 mutations across all samples.  This provided us with our final 
integrated phylogenetic trees (Fig. 2a-c) and final list of somatic point mutations (Supplementary 
Data Set 2). The structure of these trees was also supported by verified insertions, deletions and 
breakpoints (Supplementary Data Set 3 & 4 ).  The single cancer mass from Patient 6 contained 
three independent cancer clones represented by samples 6_T2, 6_T3 and 6_T4 (Fig. 2a), with a 
single verified substitution linking 6_T1/6_T2 and 6_T3. Patient 7 contained at least three 
independent cancer lineages: one (7_T3) representing the smaller cancer nodule and two 
(7_T1/7_T2 and 7_T4/7_T5) present in the larger cancer mass (Fig. 2b). Ten mutations were 
common to the morphologically normal prostate sample and to cancer samples 7_T1 and 7_T2, and 
three mutations joined 7_T4/7_T5 to the separate multifocal lesion 7_T3. These observations show 
that Prostate 7 contains at least two clones of cells that existed prior to the formation of the distinct 
cancers lineages. Prostate 8 contained two cancer lineages represented by 8_T1/8_T2 and 8_T3 (Fig. 
2c), with 43 substitutions shared between all three tumor samples, 8_T1, 8_T2 and 8_T3, 8 of which 
were also present in distant morphologically normal sample 8_N.  
Complex patterns of ERG alteration were observed in samples from Patient 6 and Patient 7 (Fig. 3); 
each main lineage contained at least one and in some cases two unique TMPRSS2-ERG fusions with 
distinct breakpoint locations within the TMPRSS2 and ERG genes (Fig. 2, Table2). The presence of 
multiple distinct TMPRSS2-ERG fusions was demonstrated by direct PCR across the breakpoint and 
by an ERG FISH break-apart assay (Table 2, Fig. 1b,c, Supplementary Fig. 1). In this respect TMPRSS-
ERG fusions could be considered to be similar to the convergent gene alterations observed in kidney 
cancer where distinct alterations of genes such as SETD2, PTEN, and KDM5C were observed in 
different parts of the same cancer10.  A deletion on Chromosome 8 exhibited a very similar pattern 
of alterations (Supplementary Fig. 7), but we did not see convergent evolution for other potential 
driver genes (Supplementary Table 3).  Where two TMPRSS2-ERG fusions existed in a single lineage 
we were unable to determine whether these fusions co-existed at any time in the same cell as 
reported previously11 and as implied by the phylogenic tree. However the FISH assay (Fig 1b,c) 
demonstrated that in sample 7_T4 the two TMPRSS2_ERG fusions were present in distinct cell 
populations at the time that the cancer sample was taken. Moreover, an additional separate ERG 
breakpoint was detected in a region of the cancer that had not been sampled in the DNA sequencing 
studies (TERG J). The occurrence of several TMPRSS2-ERG fusions is a single cancer mass is 
consistent with previous FISH-based studies reporting multiple ETS fusions in a low proportion of 
individual cancer foci11. ERG alterations are believed to represent a relatively early event in cancer 
development in agreement with their occurrence in prostatic intraepithelial neoplasia (PIN)6, but our 
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observations suggest that they may not always be present at the very first cellular expansion. 
Mutations shared either between different ERG-lineages or between cancer and morphologically 
normal tissue may represent earlier clonal cell expansions on the same lineage (Fig. 2a-c). 
Alternatively they could represent separate clones of cells within which multiple independent cancer 
lineages developed.  
Recently, we identified 21 distinct mutational signatures from 7,042 samples across 30 different 
cancer types12. The contribution of mutational processes was calculated for prostate cancer as 
previously described12,13 (Fig. 4).  A signature (designated Signature 1A in Ref. 12) associated with 
spontaneous deamination of 5-methyl-cytosine at CpG sequences explained ~50% of all of our 
mutations. Two additional signatures with unknown etiology, designated Signature 5 and Signature 
8, best explained the remaining somatic mutations. Signature 5, present in all prostate samples may 
reflect an endogenous mutational process12. Signature 8, present in two cancer samples from a 
single cancer nodule, is characterized by weak C>A strand bias.  Critically these observations show 
that the same mutational processes, giving rise to Signatures 1a and 5, are detected both in cancer 
and in matched morphologically normal prostate tissue.  We identified clustering of C>T and C>G 
mutations previously referred to as kataegis14 and complex interdependent translocations and 
deletions called chromoplexy15 in some cancer lineages (Supplementary Fig. 8 & 9). 
Next generation sequence technologies have previously been used to identify critical genetic 
processes in prostate cancer development15-19. Our results demonstrate the presence of clonal 
expansions or fields of cells in the morphologically normal prostate that provide a background 
against which prostate cancer develops. A recent study on a 115 year old woman identified 424 
point mutations, thought to result from somatic mosaicism, in the rapidly dividing tissue blood, but 
failed to detect any mutations in brain tissue20.  The presence of mutations in blood was 
accompanied by telomere attrition that was not observed in other tissues.  Prostate is considered to 
be a relatively quiescent tissue21, and we found that the telomeres in morphologically normal tissue 
from Cases 6 and 7 had not undergone attrition, being of comparable length to telomeres in 
adjacent cancer. The processes at work in morphologically normal prostate therefore appear to be 
distinct from those reported for blood (see Supplementary Notes for full discussion). Whether the 
clones of cells observed in morphologically normal prostate are generated by a pathological process 
or are the product of somatic mosaicism involving unexpectedly high mutation rates, the resulting 
clonal fields of cells may influence cancer development and/or contribute to multifocality and the 
presence of multiple cancer lineages in a single cancer mass. Evidence for a field effect in prostate 
cancer is also supported by studies demonstrating tumor-like alterations in cytomorphology, gene 
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expression, epigenetics in adjacent morphologically normal tissue, and the presence of multifocal 
disease in a high proportion of prostates. Field effects have also been proposed for oral cancer22, 
head and neck cancer23 and breast cancer24. Our results have implications for the use of cancer focal 
therapy when targeting a single nodule of cancer within the prostate25,26 and for potential 
chemotherapeutic approaches. We propose that (i) focal therapy may only be curative if 
surrounding clonal cell populations within morphologically normal tissue were also ablated, and (ii) 
cancer heterogeneity may hinder therapeutic targeting and biomarker investigation.  
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LEGENDS TO FIGURES 
Figure 1. Prostate samples chosen for whole-genome sequencing. a, ERG rearrangements 
determined by fluorescence in situ hybridization (FISH) . Case 7 is a multifocal cancer containing two 
separate foci (T1/T2/T4/T5 and T3). Case 8 is also designated as a multifocal cancer,(nodules T1/T2, 
and T3).  Yellow: un-rearranged normal ERG gene; Red, ERG gene split but both 3’ and 5’ ends 
retained; Green, ERG gene rearranged but only its 3’ end retained.  Panels b and c: 3-colour FISH 
used to distinguish different ERG-locus translocation breakpoints in Case 7. b, Position of the three 
FISH probes: probe 1 (blue, BAC RP11-164E1, and probe 1a, BACs RP11-95G19, RP11-720N21, CTD-
2511E13) was labeled in Aqua (Kreatech 415 Platinum Bright): probe 2 (red, fosmid G248P80319F5 
37Kb) labeled with Cy3; and Probe 3 (green, fosmid G248P86592E2 38.5k, and probe 4, BACs RP11-
372O17, RP11-115E14, RP11-729O4) labeled with FITC. The purple arrows represent the positions of 
ERG breakpoints detected in these experiments. For the precise position of the ERG breakpoints G 
and H see Table 2. c, Left: Tumor areas with ERG locus breaks G and H are indicated as light and dark 
green respectively. Break J was found in an adjacent prostate section not show in this figure. Right: 
representations of the ERG FISH patterns.  Original FISH images are show in Supplementary Fig. 1. 
“Split” denotes that 5’ and 3’ ERG signals were separated but retained in the cell. “Del” indicates 
that 5’ ERG signals were lost from the cell, while 3’ ERG signals were retained. 
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Figure 2. Phylogenies of multi-focal prostate cancers. a-c, Phylogenies revealing the relationships 
between sample clones for each case. Each line is associated with a clone from a particular 
sample.  The length of each line is proportional to the weighted quantity of variations on a 
logarithmic scale.  The thickness of a line indicates the proportion the clone makes up of that sample 
i.e. 48%/52% for 6_T1 and 12%/88% for 8_T3. The minor clone of 8_T3b has no detected unique 
variants. 8_T3 contained 43 mutations present as a 12% subclone (T3a) shared with 8_T1/8_T2.  In 
validation experiments 8_T3 did not contain any of the five ERG and TMPRSS2 rearrangements 
present in 8_T1/8_T2 (Table 2)) or mutations that were unique to 8_T1/8_T2 (10,000 depth) 
indicating that it represents an earlier clone of 8_T1/8_T2 seeded into tissue sample 8_T3. The 
various TMPRSS2-ERG translocations are indicated by their TERG ID (Table 2). d, Example 2D density 
plots showing the posterior distribution of the fraction of cells bearing a mutation in two samples. 
The fraction of cells is modeled using a Bayesian Dirichlet processes. These plots illustrate samples 
that have shared clonal mutations (6_T1/6_T2), and branched (unrelated) mutations (7_T2/T_T3).  
There are two examples of samples with a subclone. 7_T2/7_T5 has a peak at (0,0.72), which 
represents subclonal mutations in 72% of cells in 7_T5 that have occurred only in this sample, after 
divergence from the other samples. Similarly, 8_T1/8_T3 has a peak at (0.54,0), representing 
subclonal mutations in 54% of cells in T1 only.  
Figure 3.  Patterns of ERG alterations. a-c, Circos plots highlighting ERG rearrangements present in  
each prostate. Each color represents a different cancer sample as indicated.  
Figure 4. Relative contributions of mutational signatures to the total mutation burden of each 
sample. The mutational spectra, as defined by the triplets of nucleotides around each substitution, 
of each sample were deconvoluted into mutational processes using 22 distinct signatures 
determined from 7,042 cancers as described previously12,13. The signature designations (1a, 5, 8) 
match those reported previously12.  For sample 7_T4 and 8_N there were too few mutations to be 
able to accurately identify the contributions of the mutational signatures. 
 11 
TABLES 
Table 1 
Sample Description Gene 
Protein 
Description 
Type 
% 
reads 
Total 
num 
reads 
MA 
predicted 
functional 
impact 
ANNOVAR 
significant 
algorithms 
0006#N chr9:g.131115799G>A SLC27A4 p.V435I misssense 13.79 58 low 1 
0006#N chr14:g.20389481C>T OR4K5 p.T239M misssense 13.25 83 high 4 
0006#N chr15:g.33873844G>T RYR3 p.A525S misssense 33.33 48 medium   
0006#N chr4:g.88766379C>G MEPE p.S120* nonsense 20.83 24 
 
2 
0007#N chr5:g.150885254A>T FAT2 p.S4308T misssense 23.4 47 low 5 
0007#N chr7:g.150934857G>T CHPF2 p.R470L misssense 17.24 58 medium 5 
0007#N chr8:g.24192995G>A ADAM28 p.D470N misssense 17.78 45 neutral 2 
0007#N chr12:g.24989522G>T BCAT1 p.L276M misssense 26.47 34 medium   
 
Mutations and clonal expansions in morphologically normal tissue: point mutations present in exons 
with indication of functional significance. Missense and nonsense mutations detected and visually 
confirmed in the adjacent morphologically normal tissue were tested for functional impact using the 
MutationAssessor.org27 and wANNOVAR28 services. The OR4K5 gene was excluded as a candidate 
because of the potential to overcall mutations in genes encoding very large proteins29. Since none of 
the mutations had a high “MA” we considered that epigenetic changes may provide a more likely 
driver of clonal expansion. 
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Table 2 
Patterns of ERG alterations. Positions and structure of each ERG breakpoints and related 
rearrangements. The position and structure of the breakpoint was determined, in the majority of 
cases, by capillary sequencing using custom-designed PCR across the rearrangement breakpoint as 
previously described30 (“CS” in column “Verification”), and/or by in-silico reconstruction using local 
de novo assembly in Brass phase 2.  Verification by sizing PCR products across the breakpoint using 
gel electrophoresis was also performed (“P”).  All breakpoints were visually verified (“V”) to ensure 
the presence of discordant reads and checked that they did not occur in repeat regions.  
 
 
Donor Middle Acceptor 
    
Samples Chr Position Strand Type Seq Chr Position Strand Breakpoint Genes Verification 
TERG 
ID 
6_T1, 6_T2 21 39867180 + HOMOLOGY T 21 42877104 + deletion ERG-TMPRSS2 
CS & P (6_T1);  V (6_T1, 
6_T2) 
A 
6_T1, 6_T4 21 39877208 + HOMOLOGY T 21 42871170 + deletion ERG-TMPRSS2 P (6_T1); V (6_T1, 6_T4) B 
6_T1, 6_T4 21 39877355 - HOMOLOGY CC 21 42819405 - insertion ERG-MX1 
CS & P (6_T1); V (6_T1, 
6_T4) 
  
6_T1, 6_T4 21 39877745 + NTS CAT 21 39880855 + deletion ERG-ERG 
CS & P (6_T1); V (6_T1, 
6_T4) 
  
6_T3 20 10441211 - HOMOLOGY G 21 39872887 + translocation C20orf94-ERG CS & P & V (6_T3)   
6_T3 20 10441429 + HOMOLOGY GT 21 42868518 - translocation 
C20orf94-
TMPRSS2 
CS & P & V (6_T3)   
6_T3 21 39872930 + Exact --- 21 42868510 + deletion ERG-TMPRSS2 CS & P & V (6_T3) C 
7_T1, 7_T2 1 205613440 + HOMOLOGY C 21 42857784 - translocation _-TMPRSS2 V (7_T1, 7_T2)   
7_T1, 7_T2 2 204298424 - HOMOLOGY A 21 42849002 + translocation 
RAPH1-
TMPRSS2 
V (7_T1, 7_T2)   
7_T1, 7_T2 2 204298476 + Exact --- 19 42797705 + translocation RAPH1-CIC P (7_T1); V (7_T1, 7_T2)   
7_T1, 7_T2 10 120084722 - HOMOLOGY TG 21 42842154 + translocation 
C10orf84-
TMPRSS2 
CS & P (7_T1); V (7_T1, 
7_T2) 
  
7_T1, 7_T2 10 120084747 + HOMOLOGY AC 21 39872234 + translocation C10orf84-ERG 
CS & P (7_T2); V (7_T1, 
7_T2) 
  
7_T1, 7_T2 21 39872152 + HOMOLOGY A 21 42861527 + deletion ERG-TMPRSS2 
CS & P (7_T1); V (7_T1, 
7_T2) 
D 
7_T1, 7_T2 21 42842403 + Exact --- 21 42848506 - inversion_+ 
TMPRSS2-
TMPRSS2 
CS & P (7_T1); V (7_T1, 
7_T2) 
  
7_T2 21 39831266 + HOMOLOGY AAAC 21 42875633 + deletion ERG-TMPRSS2 CS & P & V (7_T2) E 
7_T3 21 39861568 + NTS TA 21 42865303 + deletion ERG-TMPRSS2 CS & P & V (7_T3) F 
7_T4 21 39835734 + HOMOLOGY G 21 42867100 + deletion ERG-TMPRSS2 CS & P & V (7_T4) G 
7_T4 21 42841552 - HOMOLOGY GGCT 21 42851963 + inversion_- 
TMPRSS2-
TMPRSS2 
CS & P & V (7_T4)   
7_T4, 7_T5 21 39868722 + Exact --- 21 42870051 + deletion ERG-TMPRSS2 
CS & P (7_T4); V (7_T4, 
7_T5) 
H 
8_T1, 8_T2 21 38745261 + HOMOLOGY T 21 42851601 - inversion_+ 
DYRK1A-
TMPRSS2 
P (8_T1); V (8_T1, 8_T2)   
8_T1, 8_T2 21 38745286 - HOMOLOGY A 21 42859198 - insertion 
DYRK1A-
TMPRSS2 
CS & P (8_T1); V (8_T1, 
8_T2) 
  
8_T1, 8_T2 21 39831518 + Exact --- 21 42870497 - inversion_+ ERG-TMPRSS2 
CS (8_T1); P & V (8_T1, 
8_T2) 
I 
8_T1, 8_T2 21 42844460 - HOMOLOGY T 21 42851648 + inversion_- 
TMPRSS2-
TMPRSS2 
V (8_T1, 8_T2)   
8_T1, 8_T2 21 42863787 - HOMOLOGY G 21 42870663 + inversion_- 
TMPRSS2-
TMPRSS2 
CS & P (8_T1); V (8_T1, 
8_T2) 
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ONLINE METHODS 
 
Sample Selection and Fluorescence in situ Hybridisation  
Samples for analysis were collected from prostatectomy patients at the Addenbrooke’s Hospital (see 
Supplementary Table 2). The study was approved by the Trent Multicentre Research Ethics 
Committee. Informed consent was obtained for all patients.  Prostates were sliced and processed as 
described previously31. In brief, a single 5 mm slice of the prostate was selected for research 
purposes. 4 or 6 mm cores were taken from the slice and frozen. Frozen cores were mounted 
vertically and sectioned transversely giving a single 5 µm frozen section for H&E staining followed by 
6x50 µm sections for DNA preparation. The presence of or complete absence of cancer was 
confirmed independently by three pathologists in central pathology review of the 5 µm H&E stained 
tissue slice immediately adjacent to tissue slices used for DNA preparation. The ERG fluorescence in 
situ hybridisation break-apart assay for assessing ERG gene rearrangement was performed as 
described previously6, both (i) on whole-mount formalin-fixed sections, taken immediately adjacent 
to the research slice, and (ii) on the frozen slices, immediately adjacent to the samples selected for 
DNA sequencing that had been initially subject to H&E staining. In all cases, the ERG status 
determined by these two methods and shown in Figure 1, were consistent.   
 
DNA sequencing 
Samples and Massively Parallel Sequencing 
DNA was extracted from 18 samples from 3 patients: 12 prostate cancer samples, 3 adjacent 
morphologically normal prostate samples and 3 matched bloods. Paired-end whole genome 
sequencing of the samples was performed at Illumina, Inc.  Paired-end libraries were manually 
generated from 1 µg of gDNA using the Illumina Paired End Sample Prep Kit (Catalog # PE-102-1002). 
Fragmentation was performed with Covaris E220. After end repair, A-tailing, and adapter ligation as 
per the sample prep kit instructions, libraries were manually size-selected using agarose gel 
electrophoresis, targeting 300 bp inserts. Adapter-ligated libraries were PCR amplified for 10 cycles 
and purified through a second agarose gel electrophoresis. Final libraries were QC’ed on a Agilent 
Bioanalyzer and quantified by qPCR and/or picogreen fluorimetry. Samples were clustered with 
Illumina v1.5 flowcells using the Illumina cBot with the TruSeq Paired End Cluster Kit v3. Flowcells 
were sequenced as 100 base paired-end (non-indexed) reads on the Illumina HiSeq2000 using 
TruSeq SBS chemistry v3 to a target depth of 50X for the tumour samples and 30X for adjacent 
morphologically normal and blood samples. The Burrows-Wheeler Aligner (BWA) was used to align 
the sequencing data from each lane to the GRCh37 reference human genome32. Lanes that pass 
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quality control are merged into a single well-annotated sample BAM file with duplicate reads 
removed.  This data has been submitted to the European Genome-Phenome Archive 
(EGAD00001000689). 
 
Mutation-Calling: Substitutions 
CaVEMan (Cancer Variants Through Expectation Maximization), an in-house bespoke algorithm 
developed at the Sanger Institute, was used for calling somatic substitutions. CaVEMan utilises a 
Bayesian expectation maximization (EM) algorithm: Given the reference base, copy number status 
and fraction of aberrant tumor cells present in each cancer sample, CaVEMan generates a 
probability score for potential genotypes at each genomic position. A ‘somatic’ probability of 95% 
and above was applied as a cut off.  Further post-processing filters were applied to eliminate false 
positive calls arising from genomic features that generate mapping errors and systematic sequencing 
artifacts. In addition to the standard filters applied in the Sanger pipeline we designed project-
specific filters to improve the positive predictive value of our callers based on results from visually 
inspecting and calling many hundreds of variants.  Visually inspecting involves checking that the 
variant was in at least three reads, not in any reads of control, no strand bias, no correlation of the 
reads containing the variant and read quality, not in a location where indels are also detected, not in 
a poorly mapped region, and not in a repeat region. Substitutions that are found in the WGS data of 
more than 2.5% of a batch of 465 normal non-malignant samples from a range of tissue types were 
also removed. Additional visual verification across all samples for a patient was performed for all 
non-intronic gene substitutions, all substitutions in adjacent morphologically normal samples, 
potential “field effect” substitutions, substitutions shared between adjacent morphologically normal 
and neoplastic samples, and the rare predicted substitutions apparently violating the inferred 
phylogeny. 
 
Mutation-Calling: Insertions/Deletions 
Insertions and deletions in the tumor, morphologically normal and matched blood control genomes 
were called using a modified Pindel version 0.2.0 on the NCBI37 genome build33.  As with the 
substitutions, all standard Sanger pipeline filters were applied, as well as a custom filter built based 
on results from visually calling identified variants.  Indels that were detected by Pindel in more than 
two samples from a series of hundreds of malignant non-prostate tissue were also removed.  If an 
indel detected by Pindel that does not pass the filters is found in another sample for that patient and 
does pass all filters, it is also included. From those indels that passed all filters, for each sample, up 
to one hundred variants were validated by capillary sequencing.  In addition, visual verification 
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across all samples for a patient was performed for all indels occurring within genes, all indels in 
adjacent morphologically normal samples, potential “field effect” indels, those indels that were not 
supported by the phylogeny and a sampling of variants from each phylogeny relationship. 
 
Mutation-Calling: Structural Variants 
Brass (Breakpoints via assembly), an in-house bespoke algorithm developed at the Sanger Institute, 
was used for detecting structural variants.  In Brass phase 1, discordant read pairs are detected and 
integrated to find regions of interest.  These regions of interest are removed if they have been found 
in the matched blood normal sample, have been detected as germline in PCR validation of any other 
sample, have a low numbers of reads supporting them or appear to be in a “difficult” region of the 
genome.  For a subset of regions, validation was performed by gel electrophoresis PCR using custom-
designed PCR primers across the rearrangement breakpoint as previously described34 and for those 
products that give a band the precise location and nature of the breakpoint was determined by 
standard Sanger capillary sequencing methods. In the cases where the PCR experiments failed, Brass 
phase 2 was applied to the remaining predicted somatic structural variants.  This gathers reads 
around the region, including half-unmapped reads and performs a local de novo assembly using 
Velvet35. Identifiable breakpoints have a distinctive De Bruijn graph pattern and allowed the 
breakpoint to be regenerated down to base pair resolution.  Any breakpoints where an exact 
location could not be determined were removed.  To ensure that breakpoints shared between 
samples in a patient were picked up, in-silico and PCR cross-sample experiments were performed. All 
breakpoints reported have been visually verified to ensure the presence of discordant reads and 
checked to ensure they were not in repeat regions. 
 
To detect rearrangements involved in chromoplexy, a recently described process generating chained 
rearrangements we applied ChainFinder15. We used default parameters, selecting the 
rearrangements from 57 prostate genomes as background. As input copy number data, we used 
data derived from Affymetrix SNP 6.0 arrays, and processed using ASCAT36. As input structural 
variants, for each patient, we combined all high confidence breakpoints detected in all samples of 
that patient. One chained event was manually filtered, as it combined somatic rearrangements 
present in separate subpopulations in different samples, and hence could not have occurred as one 
chromoplexy event. 
 
Mutation-Calling: Copy Number 
The Battenberg algorithm was used to detect clonal and sub-clonal somatic copy number alterations 
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(CNA) and estimate ploidy and tumour content from the NGS data as previously described9.  Briefly, 
germline heterozygous SNPs are phased using Impute2 and a- and b- alleles assigned. Data is 
segmented using piecewise constant fitting37 and subclonal copy number segments are identified as 
those with deviations in the b-allele frequencies from the values expected when all cells have a 
common copy number in that segment, using a t-test. Ploidy and tumour content are estimated 
using the same method used by ASCAT36. 
 
Construction of phylogenetic trees 
For each patient, phylogenetic trees were constructed separately using (i) copy number aberrations 
(CNAs) and (ii) point mutations. Clonal and subclonal CNAs were identified using the previously 
described Battenberg algorithm9. This method achieves high sensitivity for the detection of CNAs 
found in small proportions of cells by phasing heterozygous SNPs into parent specific haplotype 
blocks. Joint analysis of SNPs within these blocks, rather than single SNPs, allows the resolution of 
CNAs found in ~5% of cells, with 30X sequencing depth. Matching of copy number and 
rearrangement breakpoints, supported by visual inspection of allele frequency and logR plots, was 
used to identify CNAs common to multiple samples. Point mutations were analysed using an 
adaptation of a previously described Bayesian Dirichlet process. Mutations within each sample are 
modelled as deriving from an unknown number of subclones, each of which is present at an 
unknown fraction of tumour cells and contributes an unknown proportion of all somatic mutations, 
with all the unknown parameters jointly estimated. In order to identify clusters of mutations that are 
common to 2 or more samples, the Dirichlet process was extended into 2 dimensions, with the 
fraction of tumour cells bearing a mutation in each of a pair of samples jointly estimated from the 
number of reads observed in each sample. The presence of clusters of unique or shared mutations 
can be inferred from the position of the peaks in the resulting 2-dimensional probability density. 
 
Dirichlet process clustering 
We used a previously developed Bayesian Dirichlet process to model clusters of clonal and subclonal 
point mutations, allowing inference of the number of subclones, the fraction of cells within each 
subclone and the number of mutations within each clone36. Within this model, the number of reads 
bearing the ith mutation, yi, is drawn from a binomial distribution  
 
      (       )           (   ) 
 
where Ni is the total number of reads at the mutated base and ζi is the expected fraction of reads 
that would report a mutation present in 100% of tumour cells at that locus.    (   ) the fraction 
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of tumour cells carrying the ith mutation, is modelled as coming from a Dirichlet process. 
We use the stick-breaking representation of the Dirichlet process: 
 
     ∏(    )
   
  with        (   ) 
 
where ωh is the weight of the hth mutation cluster, i.e. the proportion of all somatic mutations 
specific to that cluster. This model was extended into n dimensions, where n is the number of 
related samples, with the number of mutant reads obtained from each sample modelled as an 
independent binomial distribution, each with an independent π drawn with a Dirichlet process from 
a base distribution U(0,1). Gibbs sampling was used to estimate the posterior distribution of the 
parameters of interest, implemented in R, version 2.11.1. The Markov chain was run for 500 
iterations, of which the first 100 were discarded. In order to plot the mutation density, each possible 
pair of related samples was treated separately. The median of the density was estimated from πh, 
each weighted by the associated value of ωh, using a bivariate Gaussian kernel, implemented in the 
R library KernSmooth. Median values were then plotted using the R function ‘levelplot’, using a 
colour palette graduated from white (low probability of a mutation) to red (high probability of a 
mutation). 
 
Targeted PCR and MiSeq sequencing of selected mutations and structural variants 
PCR primers for somatic substitutions and indels were designed using Primer-Z38, with known SNPs 
and human repeats masked. All amplicons were designed to be a maximum of 500 bp and all 
variants of interest were checked to be within a read generated on a 2x250bp MiSeq run.  DNA was 
amplified using Phusion HotStart II DNA polymerase kit (Thermo Fisher Scientific) and thermo cycler. 
DNA was denatured at 98 oC for 30 seconds followed by 30 cycles of denaturing at 98 oC for 10 
seconds, annealing at 65 oC for 20 seconds and extension at 72 oC for 20 seconds. Products were 
incubated at 72 oC for 5 minutes before cooling to 4 oC. All PCR products were analysed using 96 well 
2% agarose E-gel with ethidium bromide (Life Technologies). If no detectable band was present 
these reactions were repeated using an annealing temperature of 60 oC. 2 µl of PCR mixture for each 
sample of DNA were pooled. Pooled DNA was diluted 1:10, and tagged with an individual barcode 
(Fluidigm) using Expand High Fidelity PCR System (Roche), following manufacturers protocol (Access 
Array System for Illumina Systems User Guide). DNA was denatured at 98 oC for 1 minute followed 
by 15 cycles of denaturing at 98 oC for 15 seconds, annealing at 60 oC for 30 seconds and extension 
at 72 oC for 1 minute. Products were incubated at 72 oC for 3 minutes before cooling to 4 oC.  
Barcoded PCR samples were pooled for each patient and analysed using 2100 Bioanalyzer (Agilent) 
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to determine the average size of the PCR library and by KAPA SYBR FAST qPCR (Anachem) to 
determine the library concentration. 2 nM of each sample was analysed using MiSeq (Illumina). 
 
The average sequencing depth across all mutations assessed within each patient varied between 
4900 (in 8_T1) and 16600 (in 7_T4). However, for around a fifth of the targeted mutations within 
each patient, the average coverage across all samples from that patient was very much lower, 200 or 
lower. Many of these low coverage mutations had mutant allele frequencies very different from the 
values obtained from whole genome sequencing (WGS). These PCRs were considered to have failed 
and were not included in subsequent analysis. 
 
Due to the very high coverage, a low rate of sequencing errors was observed for most mutations. 
This manifested as a small percentage of aberrant reads, peaked close to zero and rapidly decaying 
exponentially with allele fraction. The rate of these errors was evaluated by considering those 
samples that reported no mutant reads in WGS. For this purpose, only mutations that were 
identified in samples that were previously identified as being phylogenetically related were included, 
in order to filter out low quality or questionable calls. Allele frequencies, fs, were converted to 
mutation copy numbers, nmut, as previously described
39. 
       
 
 
[       
        
 (   )] 
where ρ,       
  and       
  are, respectively, the tumor purity, the locus-specific copy number in the 
tumor cells and the locus-specific copy number in the blood normal cells, inferred from the 
Battenberg algorithm. Mutation copy numbers correspond to the fraction of cells bearing a mutation 
multiplied by the number of chromosomal copies bearing the mutation and are more informative 
than raw allele frequencies as they are adjusted for tumour ploidy and normal cell contamination. 
The distribution of misreads was then found to have similar distributions for the different patients, 
with average reported mutation copy numbers of 0.0059 ± 0.0072, 0.0032 ± 0.0070 and 0.0037 ± 
0.0035 in patients 6, 7 and 8, respectively. The highest reported mutation copy number for these 
mutations was 0.041. This value was therefore used as a threshold for distinguishing between 
mutations present in a small proportion of cells and misreads arising from sequencing errors. It 
should be noted that a mutation copy number of 0.041 corresponds to an allele frequency of ~1% 
for most mutations, since most mutations occur in diploid regions of the genome and the average 
tumour content across the samples is below 50%. 
For samples 6_T2, 6_T3 and 6_T4, it was apparent that nearly all mutations that were present in 
6_T1 were identified at allele fractions slightly above the threshold used to exclude artefacts 
(corresponding to a mutation copy number ~0.05). Since these mutations were exclusively those 
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present in 6_T1, it appears that ‘contamination’ of these 3 samples by 6_T1 occurred at some point 
during the PCR experiment, although whether this contamination is physical or the result of bleed-
through of tags used in multiplexing is unknown. Assessment of WGS data, by checking the allele 
frequency of mutations identified uniquely in 6_T1 in samples 6_T2, 6_T3 and 6_T4, indicated that 
there may have been some intermixing of the cells 6_T1 with 6_T2, corresponding to a much lower 
percentage of cells (1.8%) and possibly arising from growth of cells in 6_T1 into the region sampled 
in 6_T2. Further, no evidence for intermixing of 6_T1 with 6_T3 or 6_T4 was found in WGS data. For 
this reason, mutations apparently present in the PCR experiment in 6_T2, 6_T3 and 6_T4 and 
identified in 6_T1 in both WGS and PCR were only considered to be validated if they fell above a 
higher threshold, set to a mutation copy number of 0.2, that excluded mutant reads arising from the 
contamination of these samples. 
 
Mutational Signatures 
The mutational spectra, as defined by the triplets of nucleotides around each mutation, of each 
sample was deconvoluted into mutational processes as described12,13. 
 
Clustering of Mutations 
We investigated regional clustering of substitution mutations by constructing plots (“rainfall plots”) 
in which the distance between each somatic substitution, and the substitution immediately before it 
has been plotted for each mutation. This was achieved exactly as described previously9. 
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